Corbel Capital Partners has closed a structured investment to support the revitalization of Skalar Pharma Holding LLC's advanced pharmaceutical ingredient production facility in Puerto Rico.
Target Information
Skalar Pharma Holding LLC, known simply as Skalar, is the owner of a cutting-edge active pharmaceutical ingredient (API) production facility located in Guyama, Puerto Rico. This state-of-the-art campus is equipped with advanced production infrastructure capable of manufacturing complex molecular medicines. Originally built by Astra Zeneca in 1992, the facility has a robust history, having been certified by leading regulatory agencies in the United States, Europe, and Asia.
Over the years, the plant has successfully produced more than 30 different complex molecules. It was most recently owned by Eli Lilly, where it served as a global supplier of APIs before Skalar acquired it. The current leadership of Skalar is bolstered by Fernando Londono, its chairman, who brings extensive experience and expertise from his successful career in the biopharmaceutical sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Puerto Rico
The pharmaceutical industry in Puerto Rico has a well-established reputation, thanks to its strong regulatory framework and highly skilled workforce. The island serves as a key manufacturing hub for
Similar Deals
Hark Capital → Pharos IV-A, L.P.
2025
Corbel Capital Partners
invested in
Skalar Pharma Holding LLC
in 2021
in a Venture Debt deal